AMAG Pharmaceuticals (NASDAQ:AMAG) was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research report issued on Friday.

Several other analysts also recently commented on the stock. BidaskClub downgraded shares of AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, May 28th. B. Riley upped their price objective on shares of AMAG Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a report on Monday, August 6th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $22.00 price objective on shares of AMAG Pharmaceuticals in a report on Friday, August 3rd. Leerink Swann started coverage on shares of AMAG Pharmaceuticals in a report on Monday, May 21st. They issued a “market perform” rating and a $24.65 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and issued a $18.00 price objective (up from $17.00) on shares of AMAG Pharmaceuticals in a report on Friday, August 3rd. Seven research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. AMAG Pharmaceuticals has a consensus rating of “Hold” and an average target price of $22.85.

AMAG Pharmaceuticals stock traded down $0.50 during mid-day trading on Friday, reaching $22.45. 548,400 shares of the company traded hands, compared to its average volume of 867,782. The company has a current ratio of 2.06, a quick ratio of 1.95 and a debt-to-equity ratio of 0.99. AMAG Pharmaceuticals has a fifty-two week low of $11.93 and a fifty-two week high of $26.10. The firm has a market capitalization of $801.49 million, a price-to-earnings ratio of -3.93 and a beta of 0.48.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.54). AMAG Pharmaceuticals had a negative net margin of 36.87% and a negative return on equity of 2.77%. The company had revenue of $146.25 million for the quarter, compared to analyst estimates of $156.26 million. During the same quarter in the previous year, the company posted ($0.40) EPS. The company’s revenue for the quarter was up 12.2% compared to the same quarter last year. sell-side analysts predict that AMAG Pharmaceuticals will post -3.31 EPS for the current fiscal year.

In other news, CEO William K. Heiden sold 5,000 shares of the company’s stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the sale, the chief executive officer now directly owns 328,015 shares of the company’s stock, valued at approximately $8,200,375. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.00% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the company. FMR LLC boosted its holdings in AMAG Pharmaceuticals by 49.4% during the second quarter. FMR LLC now owns 1,991,368 shares of the specialty pharmaceutical company’s stock worth $38,832,000 after buying an additional 658,100 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in AMAG Pharmaceuticals by 6.2% during the second quarter. Renaissance Technologies LLC now owns 1,641,100 shares of the specialty pharmaceutical company’s stock worth $32,001,000 after buying an additional 96,300 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in AMAG Pharmaceuticals by 13.7% during the second quarter. Russell Investments Group Ltd. now owns 1,170,332 shares of the specialty pharmaceutical company’s stock worth $22,878,000 after buying an additional 140,741 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its holdings in AMAG Pharmaceuticals by 25.0% during the second quarter. Robeco Institutional Asset Management B.V. now owns 975,748 shares of the specialty pharmaceutical company’s stock worth $19,026,000 after buying an additional 195,217 shares in the last quarter. Finally, Macquarie Group Ltd. boosted its holdings in AMAG Pharmaceuticals by 3,646.1% during the second quarter. Macquarie Group Ltd. now owns 516,956 shares of the specialty pharmaceutical company’s stock worth $10,081,000 after buying an additional 503,156 shares in the last quarter.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Read More: Average Daily Trade Volume Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.